Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis
动脉粥样硬化中体细胞 TET2 突变驱动的克隆造血
基本信息
- 批准号:9913594
- 负责人:
- 金额:$ 40.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adoptive Cell TransfersAdoptive TransferAffectAgeAgingArterial Fatty StreakAtherosclerosisBloodBlood CellsBlood VesselsBone MarrowCardiovascular DiseasesCause of DeathCellsCessation of lifeCholesterolClinicalClinical ResearchClonal ExpansionDNA Sequence AlterationDevelopmentDiseaseElderlyEnsureEtiologyExhibitsFrequenciesFunctional disorderFutureGenesGrowthHematopoiesisHematopoieticHematopoietic SystemHepaticHumanIncidenceIndividualInterleukin-1 betaInterventionInvestigationLinkMalignant NeoplasmsMediatingMethodologyModelingMolecularMusMutateMutationNatureNodalPharmaceutical PreparationsPharmacologyPre-Clinical ModelPreclinical TestingPreventive careResearchRoleScienceSomatic MutationSystems DevelopmentTestingTimeTissuesVirusage relatedatherogenesisbaseclinically relevantexome sequencingexperimental studyin vivoinsightloss of functionmacrophagemouse modelmutantpersonalized medicinepreventprophylactictargeted treatment
项目摘要
ABSTRACT
The accumulation of somatic DNA mutations over time is a hallmark of aging in many tissues. However, the
causal role of somatic mutations in age-associated disorders other than cancer is a matter of debate and
remains largely unexplored in the setting of cardiovascular disease. Recent large exome sequencing studies in
humans have shown that aging is inevitably associated with an increased frequency of somatic mutations in
the hematopoietic system, which provide a competitive growth advantage to the mutant cell and thus allow its
clonal expansion (somatic mutation-driven clonal hematopoiesis). Supporting this notion, our recent study in
Science (Fuster et al, Science 2017) demonstrated that the clonal expansion of hematopoietic cells deficient in
TET2, one of the most frequently mutated genes in blood cells of elderly individuals, accelerates
atherosclerotic plaque formation (atherogenesis) in hyperlipidemic mice. While this study provided
experimental evidence of causality and mechanistic insight supporting that somatic mutations in blood cells are
a new contributor to atherosclerotic cardiovascular disease, there are limitations in extrapolating these results
to the clinical scenario. Specifically, in our experimental study, clonal hematopoiesis preceded atherosclerotic
plaque induction; however, clinical studies show that substantial subclinical atherosclerosis is already present
in most individuals at ages that typically precede the development of somatic mutation driven-clonal
hematopoiesis. Furthermore, an increasing percentage of individuals are prophylactically treated with
cholesterol-lowering drugs, but the impact of clonal hematopoiesis in plaque arrest/regression induced by
blood cholesterol lowering remains completely unexplored. Based on these clinical facts, the overarching
objective of this proposal is to investigate whether somatic TET2 mutation-driven clonal hematopoiesis affects
atherosclerosis in the clinically relevant settings of atherosclerotic plaque progression or arrest/regression. Aim
1 will evaluate the effects of the clonal expansion of TET2-deficient hematopoietic cells in atherosclerotic
plaque progression in hyperlipidemic mice and in plaque arrest/regression induced by blood cholesterol
lowering. Aim 2 will dissect the molecular mechanisms underlying the effects of TET2 mutations in plaque
remodeling. Aim 3 will explore the hypothesis that interventions targeting mechanistic nodal points downstream
of TET2 deficiency in the hematopoietic system protect against accelerated atherosclerosis in mice exhibiting
TET2 loss of function-driven clonal hematopoiesis.
摘要
随着时间的推移,体细胞DNA突变的积累是许多组织衰老的标志。但
体细胞突变在除癌症以外的年龄相关疾病中的因果作用是一个有争议的问题,
在心血管疾病的情况下仍然很大程度上未被探索。最近的大外显子组测序研究
人类已经表明,衰老不可避免地与增加的体细胞突变频率有关,
造血系统,其为突变细胞提供竞争性生长优势,从而允许其
克隆扩增(体细胞突变驱动的克隆造血)。支持这一观点,我们最近的研究,
Science(Fuster et al,Science 2017)证明,造血细胞的克隆扩增在造血干细胞中缺乏。
TET 2是老年人血细胞中最常突变的基因之一,
动脉粥样硬化斑块形成(动脉粥样硬化形成)。虽然这项研究提供了
因果关系和机械见解的实验证据支持血细胞中的体细胞突变是
动脉粥样硬化性心血管疾病的新贡献者,在推断这些结果时存在局限性
到临床上。具体来说,在我们的实验研究中,
斑块诱导;然而,临床研究表明已经存在大量亚临床动脉粥样硬化
在大多数个体中,通常在体细胞突变发展之前的年龄,
造血此外,越来越多的人接受了
降低胆固醇的药物,但克隆造血的影响,在斑块停滞/消退诱导
降低血胆固醇仍然完全未被探索。基于这些临床事实,
本提案的目的是研究体细胞TET 2突变驱动的克隆造血是否影响
在动脉粥样硬化斑块进展或停滞/消退的临床相关环境中的动脉粥样硬化。目的
1将评估TET 2缺陷造血细胞克隆扩增在动脉粥样硬化中的作用。
高脂血症小鼠中的斑块进展和血液胆固醇诱导的斑块停滞/消退
降低。目的2将剖析TET 2突变在斑块中作用的分子机制
重塑目标3将探讨针对下游机制节点的干预措施的假设
造血系统中TET 2缺乏的小鼠可防止加速动脉粥样硬化,
TET 2功能驱动的克隆造血功能丧失。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Coleen A McNamara其他文献
406-5 Oxidized low-density lipoprotein-stimulated smooth muscle cell growth is mediated by the helix loop helix factor Id3: A novel mechanism contributing to atherosclerotic lesion formation
- DOI:
10.1016/s0735-1097(04)92264-4 - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
Angela M Taylor;Feng Li;Ross Gerrity;Richard L Birnbaum;Martin Matsumura;Sarah Rutherford;Puspha-Rekha Thimmalapura;Coleen A McNamara - 通讯作者:
Coleen A McNamara
Coleen A McNamara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Coleen A McNamara', 18)}}的其他基金
Id3 and VSMC in Murine and Human Atherosclerosis
Id3 和 VSMC 在小鼠和人类动脉粥样硬化中的作用
- 批准号:
10004164 - 财政年份:2019
- 资助金额:
$ 40.38万 - 项目类别:
Id3 and VSMC in Murine and Human Atherosclerosis
Id3 和 VSMC 在小鼠和人类动脉粥样硬化中的作用
- 批准号:
10421070 - 财政年份:2019
- 资助金额:
$ 40.38万 - 项目类别:
Id3 and VSMC in Murine and Human Atherosclerosis
Id3 和 VSMC 在小鼠和人类动脉粥样硬化中的作用
- 批准号:
10210435 - 财政年份:2019
- 资助金额:
$ 40.38万 - 项目类别:
Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis
动脉粥样硬化中体细胞 TET2 突变驱动的克隆造血
- 批准号:
10397523 - 财政年份:2018
- 资助金额:
$ 40.38万 - 项目类别:
B Cell Subsets in Mouse and Human Atherosclerosis
小鼠和人类动脉粥样硬化中的 B 细胞亚群
- 批准号:
10188607 - 财政年份:2017
- 资助金额:
$ 40.38万 - 项目类别:
Project 3: Regulation of atheroprotective IgM - producing B cells in murine and human atherosclerosis
项目 3:调节小鼠和人类动脉粥样硬化中产生动脉粥样硬化 IgM 的 B 细胞
- 批准号:
10334096 - 财政年份:2017
- 资助金额:
$ 40.38万 - 项目类别:
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection
B 淋巴细胞主动脉归巢和动脉粥样硬化的基因调控
- 批准号:
8433454 - 财政年份:2011
- 资助金额:
$ 40.38万 - 项目类别:
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection
B 淋巴细胞主动脉归巢和动脉粥样硬化的基因调控
- 批准号:
8607987 - 财政年份:2011
- 资助金额:
$ 40.38万 - 项目类别:
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection
B 淋巴细胞主动脉归巢和动脉粥样硬化的基因调控
- 批准号:
8243525 - 财政年份:2011
- 资助金额:
$ 40.38万 - 项目类别:
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection
B 淋巴细胞主动脉归巢和动脉粥样硬化的基因调控
- 批准号:
8083888 - 财政年份:2011
- 资助金额:
$ 40.38万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 40.38万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 40.38万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 40.38万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 40.38万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 40.38万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 40.38万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 40.38万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 40.38万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 40.38万 - 项目类别: